Gregor Habl
Papers
1
Total Citations
3
H-Index
1
About
Gregor Habl is a radiation oncologist whose research centers on stereotactic ablative body radiotherapy (SABR) and image-guided radiosurgery for treating recurrent prostate cancer. His most notable contribution is demonstrating the efficacy of single-fraction robotic radiosurgery in controlling local prostate cancer recurrence after radical prostatectomy. In a pivotal 2020 study, Habl and his team treated 35 patients with biochemical failure using single-fraction SABR, achieving promising local control rates while maintaining a favorable toxicity profile. This work has garnered 3 citations and represents an important step toward non-invasive, ultra-hypofractionated salvage treatment options. Habl’s research addresses the critical challenge of managing post-prostatectomy recurrence, offering patients a precise, single-session alternative to conventional fractionated radiotherapy. His findings contribute to the growing body of evidence supporting stereotactic body radiotherapy in the oligorecurrent setting, potentially reducing treatment burden while maintaining oncologic outcomes. Through this work, Habl advances the field of prostate cancer radiotherapy by refining dose delivery and patient selection for salvage radiosurgery.
Research Focus
Key Achievements
Top Papers
- 1